03:38 , Jan 11, 2019 |  BC Innovations  |  Product R&D

PureTech turns inward

After a 15-year run of spinning out technologies into affiliate companies, PureTech Health plc is stepping away from that model in favor of an internal pipeline to advance its new platforms. Behind the structural shift...
17:03 , Jan 4, 2019 |  BC Week In Review  |  Financial News

China's Antengene raises $120M series B round

Antengene Corp. (Shanghai, China) completed a $120 million series B round on Jan. 2 to fund development of its two lead cancer compounds, selinexor and ATG-008. Boyu Capital and FountainVest led the round, with participation...
01:05 , Jan 4, 2019 |  BC Week In Review  |  Company News

Xynomic returns to Boehringer for second cancer candidate

Xynomic Pharmaceuticals (Dover, Del.) gained exclusive, worldwide rights to BI 860585 from Boehringer Ingelheim GmbH (Ingelheim, Germany). Response from Xynomic Business Development Manager Angela Fung told BioCentury that Xynomic will pay Boehringer up to $800...
21:56 , Jan 2, 2019 |  BC Extra  |  Financial News

China's Antengene raises $120M series B round

Antengene Corp. (Shanghai, China) completed a $120 million series B round to fund development of its two lead cancer compounds, selinexor and ATG-008. Boyu Capital and FountainVest led the round, with participation by Celgene Corp....
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
20:11 , Nov 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Heart transplant rejection Mouse studies suggest APOA/phospholipid-based nanoparticles loaded with rapamycin or a TRAF6 inhibitor could help prevent heart transplant rejection. The nanoparticles consist of APOA and natural phospholipid components of HDL cholesterol isolated...
17:40 , Oct 19, 2018 |  BC Week In Review  |  Company News

Revolution acquiring Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
00:55 , Oct 19, 2018 |  BC Innovations  |  Translation in Brief

Sorting out exosomes

A team of Japanese researchers have identified UBL3 as a new therapeutic target for cancers and neurodegenerative diseases that spread via the exosome-based intercellular communication system. The ubiquitin system sorts proteins for cellular export via...
22:17 , Oct 16, 2018 |  BC Extra  |  Company News

Revolution acquiring fellow Third Rock company Warp Drive

Revolution Medicines Inc. (Redwood City, Calif.) is expanding its cancer pipeline with the acquisition of another Third Rock Ventures portfolio company, Warp Drive Bio Inc. (Cambridge, Mass.). The financial terms of the deal are undisclosed...
00:33 , Sep 28, 2018 |  BC Innovations  |  Targets & Mechanisms

Cell metabolism’s migration

As cancer metabolism undergoes a renaissance in the clinic, with compounds targeting growth factor and nutrient sensing pathways, basic research on metabolic processes in all cells is shining light on pathways that could yield new...